Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Total Current Liabilities
All obligations due within one year.
Korro Bio, Inc.NASDAQ: KRRO
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 14.8% from a year ago
Total current liabilities stood at $14.79M at the end of Q1 FY2026, up 14.8% from a year earlier and up 23.9% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.
Context
- Total current liabilities amounted to 8.1% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +14.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 11.94M USD
- Year-over-year change
- -20.2%
- 4-year CAGR
- +1.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.94M | -20.2% |
| FY2024 | 2024-12-31 | 14.96M | -23.2% |
| FY2023 | 2023-12-31 | 19.48M | +123.9% |
| FY2022 | 2022-12-31 | 8.7M | -23.9% |
| FY2021 | 2021-12-31 | 11.43M | — |
Total Current Liabilities vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's Mar 2026 total current liabilities of $14.79M is the 7th highest of the 11 companies compared; the peer median is $19.1M.
- Its year-over-year change of +14.8% is the 8th highest of 11, against a peer median of +23.8%.
- Total current liabilities amounts to 8.1% of total assets for KRRO, versus a peer median of 10.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $179.64M | +10.6% | -9.2% | 27.8% | |
| Mar 2026 | $51.8M | +28.3% | +25.3% | 19.4% | |
| Mar 2026 | $47.76M | +115.8% | +82.2% | 22.9% | |
| Mar 2026 | $35.94M | +7.1% | +24.0% | 13.7% | |
ENGNenGene Holdings Inc. | Apr 2026 | $21.49M | +19.4% | +229.6% | 7.0% |
| Mar 2026 | $16.71M | +37.4% | +20.7% | 12.1% | |
| Mar 2026 | $14.79M | +14.8% | +11.1% | 8.1% | |
| Mar 2026 | $13.12M | +80.7% | +26.8% | 4.7% | |
| Mar 2026 | $11.32M | +15.6% | -4.2% | 3.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $10.91M | +179.2% | +151.3% | 2.8% |
| Mar 2026 | $10.46M | -45.7% | -14.7% | 9.1% | |
| Peer median (excluding KRRO) | $19.1M | +23.8% | +24.6% | 10.6% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 79.64M | 36.94M | 166.15M | 55.64M | 21.82M |
| Short-term Investments | 51.07M | 18.92M | 0 | 70.45M | 53.33M |
| Net Receivables | 144K | 0 | 0 | 1.7M | 969K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.04M | (376K) | 3.56M | 3.74M | 6.25M |
| Total Current Assets | 134.75M | 57.08M | 172.73M | 131.53M | 82.37M |
| Property, Plant & Equipment (Net) | 36.87M | 11.89M | 42.82M | 51.55M | 16.22M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 13.42M | 4.54M | 3.41M | 36.96M | 12.44M |
| Tax Assets | 0 | 0 | 0 | 0 | 2.2M |
| Other Non-current Assets | 320K | 228K | 2.71M | 6.2M | 270K |
| Total Non-current Assets | 50.61M | 16.66M | 48.94M | 94.71M | 31.13M |
| Total Assets | 185.36M | 73.74M | 221.66M | 226.24M | 113.51M |
| Account Payables | 2.75M | 2.61M | 7.28M | 3.99M | 1.65M |
| Short-term Debt | 2.58M | 2.92M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 3.51M | 7.84M |
| Other Current Liabilities | 1.73M | 551K | 395K | 4.05M | (3.72M) |
| Total Current Liabilities | 11.43M | 8.7M | 19.48M | 14.96M | 11.94M |
| Long-term Debt | 14.17M | 163.86M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 5.91M | 7.84M |
| Other Non-current Liabilities | 87K | 163.86M | 1.05M | 1.47M | 1.48M |
| Total Non-current Liabilities | 43.11M | 164.07M | 32.27M | 50.87M | 50.13M |
| Total Liabilities | 54.53M | 172.77M | 51.75M | 65.83M | 62.07M |
| Common Stock | 35K | 0 | 8K | 9K | 9K |
| Retained Earnings | (180.09M) | (101.83M) | (183.01M) | (266.59M) | (383.85M) |
| Accumulated OCI | (62K) | (5K) | (0) | 268K | 212K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 130.82M | (99.03M) | 169.91M | 160.42M | 51.44M |
| Total Debt | 45.6M | 166.99M | 33.21M | 44.77M | 43.49M |
| Net Debt | (34.04M) | 130.06M | (132.94M) | (10.88M) | 21.66M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.